Skip to main content

Myelodysplastic Syndromes (MDS)

Reviewed 06/2018
 


BASICS

DESCRIPTION

  • Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal stem cell disorders characterized by peripheral blood cytopenias: anemia, thrombocytopenia, and/or neutropenia.

  • Dys...

DIAGNOSIS

HISTORY

  • The clinical course of MDS patients is driven by the type and degree of cytopenias.

  • Recurrent infections, bleeding issues, fatigue, weight loss and exertional dyspnea, are common sympt...

TREATMENT

GENERAL MEASURES

  • LR-MDS: observation until patients develop symptoms from anemia, neutropenia, and/or thrombocytopenia

    • Initial treatment is tailored based on the specific cytopenia.

  • In higher...

ONGOING CARE

FOLLOW UP RECOMMENDATIONS

Patient Monitoring

  • Follow-up of MDS is based on regular complete blood counts, to detect the need for transfusions. Severe neutropenia may indicate antibiotic use ...

REFERENCES

1
Visconte V, Tiu RV, Rogers HJ. Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease. Blood Res.  2014;49(4):216–227. [View Abs...

CODES

ICD10

  • D46.9 Myelodysplastic syndrome, unspecified

  • D46.4 Refractory anemia, unspecified

  • D46.B Refract cytopenia w multilin dysplasia and ring sideroblasts

  • D64.3 Other sideroblastic anemias

  • D46.A Refra...

CLINICAL PEARLS

  • MDS are a heterogeneous group of clonal stem cell disorders characterized by blood cytopenias and tendency for leukemic transformation.

  • Different molecular and genetic mechanisms of pat...

Subscribe to Access Full Content

Sign Up for a 10-Day Free Trial

Sign up for a 10-day FREE Trial now and receive full access to all content.

 
×